ABIM GI common mistakes
ABIM GI · Understand the traps and how to avoid them.
Choosing the single most likely diagnosis and moving on, instead of systematically excluding the dangerous alternative that the stem is built to test (e.g., calling chest pain with a normal ECG 'GERD' without considering esophageal or cardiac mimics).
Exam stems are engineered so the obvious answer is the tempting distractor; candidates pattern-match to the first recognizable syndrome rather than asking 'what would kill this patient or what is the stem signaling with its atypical features?'
What to do instead
Before committing, ask 'what is the worst diagnosis that fits and what feature rules it in or out?' Re-read the stem for one discordant detail (weight loss, dysphagia, nocturnal symptoms, anemia) and confirm your choice accounts for it.
Managing upper GI bleeding or dyspepsia without first stratifying by risk (hemodynamic status, transfusion threshold, need for urgent endoscopy, H. pylori testing/eradication, NSAID cessation) and jumping straight to a drug choice.
Candidates treat these as pharmacology questions and forget the resuscitation/triage layer that precedes drug selection; the stem often hides instability in vitals or a falling hemoglobin.
What to do instead
For every bleeding or ulcer stem, run a fixed checklist: hemodynamics, risk score, timing of endoscopy, PPI, H. pylori test-and-treat, and NSAID/anticoagulant review. Answer the resuscitation question before the drug question.
Working up chronic diarrhea or malabsorption without first separating secretory vs osmotic vs inflammatory vs malabsorptive physiology, then ordering tests in the wrong sequence (e.g., sending celiac serologies before confirming steatorrhea or excluding infection).
The differential is broad and candidates shotgun tests instead of using stool studies, response to fasting, and fecal markers to narrow the category first.
What to do instead
Commit to a category using stool osmotic gap, response to fasting, fecal calprotectin, and stool cultures/parasites before selecting specific tests. Then match the test to the category (celiac serology plus duodenal biopsy for malabsorption; breath testing or trial for bacterial overgrowth; imaging for structural disease).
Treating lower GI symptoms as a single disease (e.g., labeling all chronic diarrhea as IBS) without excluding alarm features, medication causes, microscopic colitis, or colorectal cancer risk.
IBS is common and satisfying to diagnose, so candidates anchor on it and skip the red-flag and medication review that the stem deliberately plants.
What to do instead
Enumerate alarm features (age, weight loss, anemia, hematochezia, nocturnal symptoms, family history) and medication/supplement causes explicitly. If any are present, state the structural workup (colonoscopy with biopsies for microscopic colitis) before accepting a functional diagnosis.
Confusing the diagnostic criteria and management of acute pancreatitis versus chronic pancreatitis versus autoimmune pancreatitis, and mis-stratifying severity (fluid resuscitation, enteral feeding timing, ERCP indications, pseudocyst vs necrosis).
The three entities share enzymes and imaging findings, and candidates memorize isolated facts without a framework linking etiology, imaging, and severity scoring.
What to do instead
Build a one-page matrix: acute (lipase >3x, imaging, severity by organ failure, early enteral nutrition, no prophylactic antibiotics, ERCP only with cholangitis or obstruction), chronic (calcifications, steatorrhea, enzyme replacement, diabetes), autoimmune (IgG4, steroid response, imaging). Answer by locating the stem in the matrix first.
Interpreting liver tests without a pattern-based algorithm (hepatocellular vs cholestatic, acute vs chronic, isolated hyperbilirubinemia) and failing to sequence serologies, imaging, and biopsy appropriately.
Candidates jump to a favorite diagnosis (e.g., autoimmune hepatitis or PBC) from a single abnormal value rather than using the R factor and timeline to constrain the differential.
What to do instead
Calculate the hepatocellular vs cholestatic pattern, check whether the abnormality is acute or chronic, then apply a fixed serologic panel (viral, autoimmune, iron/copper, metabolic) and imaging (ultrasound first, then MRCP or elastography). Justify each test by the pattern it distinguishes.
Managing IBD by habit rather than by disease location, severity, and complication (e.g., choosing a biologic before confirming infectious colitis is excluded, missing toxic megacolon, or misjudging when surgery is indicated).
IBD management has many moving parts and candidates apply a memorized drug ladder without first excluding infection, assessing severity, or recognizing fulminant disease requiring urgent escalation.
What to do instead
For every IBD stem, answer in order: exclude infection (stool studies), define extent and severity, identify complications (stricture, fistula, toxic megacolon, dysplasia surveillance), then select therapy. State explicitly why surgery or hospitalization is or is not indicated.
Failing to connect lesion location and histology to the correct hereditary syndrome and surveillance plan (e.g., calling multiple gastric or duodenal polyps 'sporadic' or missing Lynch syndrome criteria in a colorectal cancer stem).
Syndromes present with overlapping findings and candidates recognize the syndrome name without knowing the associated cancer risks, genetic testing criteria, and organ-specific surveillance intervals that the question actually tests.
What to do instead
For each polyp or cancer stem, list lesion type, location, number, and family history, then map to a syndrome and state the gene, extracolonic risks, and surveillance for each organ. Memorize the surveillance table rather than the syndrome name alone.
Answering nutrition, obesity, and malabsorption questions with a single intervention (e.g., 'give TPN' or 'start a GLP-1') without addressing route, refeeding risk, micronutrient deficiencies, or the contraindication the stem embeds.
These topics feel like lifestyle questions, so candidates skip the metabolic and safety layer (refeeding syndrome, electrolyte monitoring, aspiration risk, bariatric surgery complications and supplementation).
What to do instead
For every nutrition stem, check refeeding risk (low BMI, low phosphate, rapid weight loss), choose enteral over parenteral when the gut works, and specify monitoring and supplementation. For obesity, name the contraindication and follow-up before naming the drug.
Treating endoscopy and periprocedural care as an afterthought: ignoring sedation risk assessment, anticoagulation/antiplatelet management, antibiotic prophylaxis indications, and post-procedure complication timelines.
Candidates focus on the procedure's diagnostic yield and forget the peri-procedural safety framework that the question is usually testing.
What to do instead
For each procedure stem, run a fixed sequence: indication, sedation/ASA class, antithrombotic hold and restart timing, prophylaxis need (rarely indicated for GI endoscopy), and expected complication timing (perforation, bleeding, pancreatitis, post-polypectomy syndrome). Answer the safety question before the diagnostic one.
Missing GI manifestations of systemic or infectious disease because the stem leads with a non-GI complaint (e.g., vasculitis, amyloidosis, tuberculosis, HIV-related disease, or infectious colitis masquerading as IBD).
Candidates compartmentalize by organ system and do not cross-reference systemic findings (rash, renal failure, neuropathy, eosinophilia, travel, immunosuppression) with GI symptoms.
What to do instead
When a GI complaint is accompanied by extraintestinal findings, deliberately list systemic diseases with GI involvement and infectious exposures before concluding a primary GI disorder. Ask 'what systemic disease explains the GI finding plus this non-GI finding?'